UBS Group
TGTX icon

UBS Group’s TG Therapeutics TGTX Stock Holding History

UBS Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.3M Buy
515,162
+9,512
+2% +$389K ﹤0.01% 2320
2026
Q1 		$16.8M Sell
505,650
-31,369
-6% -$935K ﹤0.01% 2794
2025
Q4 		$16M Sell
537,019
-81,209
-13% -$2.65M ﹤0.01% 2797
2025
Q3 		$22.3M Buy
618,228
+86,787
+16% +$2.86M ﹤0.01% 2433
2025
Q2 		$19.1M Sell
531,441
-100,250
-16% -$3.73M ﹤0.01% 2405
2025
Q1 		$24.9M Sell
631,691
-15,406
-2% -$518K ﹤0.01% 2134
2024
Q4 		$19.5M Sell
647,097
-18,858
-3% -$541K ﹤0.01% 2348
2024
Q3 		$15.6M Buy
665,955
+145,723
+28% +$3.18M ﹤0.01% 2027
2024
Q2 		$9.25M Sell
520,232
-4,390
-0.8% -$70K ﹤0.01% 2269
2024
Q1 		$7.98M Sell
524,622
-40,214
-7% -$641K ﹤0.01% 2480
2023
Q4 		$9.65M Buy
564,836
+209,271
+59% +$2.43M ﹤0.01% 2129
2023
Q3 		$2.97M Buy
355,565
+210,173
+145% +$2.93M ﹤0.01% 3063
2023
Q2 		$3.61M Sell
145,392
-121,488
-46% -$3.14M ﹤0.01% 2902
2023
Q1 		$4.01M Sell
266,880
-188,887
-41% -$2.87M ﹤0.01% 2729
2022
Q4 		$5.39M Buy
455,767
+433,782
+1,973% +$3.15M ﹤0.01% 2432
2022
Q3 		$131K Sell
21,985
-113,366
-84% -$744K ﹤0.01% 5471
2022
Q2 		$576K Sell
135,351
-18,572
-12% -$116K ﹤0.01% 4160
2022
Q1 		$1.46M Sell
153,923
-99,869
-39% -$1.16M ﹤0.01% 3740
2021
Q4 		$4.82M Buy
253,792
+172,501
+212% +$4.48M ﹤0.01% 2859
2021
Q3 		$2.71M Buy
81,291
+74,994
+1,191% +$2.32M ﹤0.01% 3313
2021
Q2 		$244K Sell
6,297
-41,303
-87% -$1.62M ﹤0.01% 5217
2021
Q1 		$2.29M Buy
47,600
+39,630
+497% +$1.9M ﹤0.01% 3423
2020
Q4 		$415K Sell
7,970
-579
-7% -$19.6K ﹤0.01% 4753
2020
Q3 		$229K Buy
8,549
+2,122
+33% +$48.8K ﹤0.01% 4715
2020
Q2 		$125K Sell
6,427
-61,456
-91% -$990K ﹤0.01% 5129
2020
Q1 		$668K Buy
67,883
+33,383
+97% +$422K ﹤0.01% 3706
2019
Q4 		$383K Sell
34,500
-240,699
-87% -$1.83M ﹤0.01% 5074
2019
Q3 		$1.54M Buy
275,199
+59,606
+28% +$416K ﹤0.01% 3558
2019
Q2 		$1.86M Buy
215,593
+190,407
+756% +$1.44M ﹤0.01% 3209
2019
Q1 		$203K Sell
25,186
-339,197
-93% -$1.83M ﹤0.01% 4591
2018
Q4 		$1.49M Buy
364,383
+323,887
+800% +$1.61M ﹤0.01% 3315
2018
Q3 		$226K Buy
40,496
+3,559
+10% +$40.7K ﹤0.01% 4967
2018
Q2 		$486K Sell
36,937
-166,923
-82% -$2.3M ﹤0.01% 4332
2018
Q1 		$2.9M Buy
203,860
+128,766
+171% +$1.65M ﹤0.01% 2797
2017
Q4 		$616K Sell
75,094
-40,365
-35% -$353K ﹤0.01% 4139
2017
Q3 		$1.37M Buy
115,459
+96,960
+524% +$1.1M ﹤0.01% 3440
2017
Q2 		$186K Buy
18,499
+3,893
+27% +$43.6K ﹤0.01% 4790
2017
Q1 		$171K Buy
14,606
+3,736
+34% +$26.8K ﹤0.01% 4738
2016
Q4 		$50K Buy
10,870
+3,873
+55% +$22.7K ﹤0.01% 5838
2016
Q3 		$54K Sell
6,997
-793
-10% -$5.1K ﹤0.01% 5452
2016
Q2 		$48K Sell
7,790
-4,114
-35% -$33.4K ﹤0.01% 5557
2016
Q1 		$101K Sell
11,904
-63,280
-84% -$554K ﹤0.01% 4976
2015
Q4 		$897K Buy
75,184
+57,113
+316% +$721K ﹤0.01% 3500
2015
Q3 		$182K Buy
18,071
+11,471
+174% +$171K ﹤0.01% 4712
2015
Q2 		$110K Sell
6,600
-500
-7% -$7.92K ﹤0.01% 5319
2015
Q1 		$110K Sell
7,100
-1,385
-16% -$21K ﹤0.01% 5338
2014
Q4 		$135K Buy
+8,485
New +$110K ﹤0.01% 5402

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

UBS Group's TGTX Position: Q2 2026 in Review

UBS Group increased its TG Therapeutics (TGTX) stake by 1.9% in Q2 2026, buying an estimated $389K and bringing the position to 515,162 shares worth $28.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2320.

UBS Group first reported a position in TGTX in Q4 2014 and has held it in 47 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • UBS Group held 515,162 shares of TG Therapeutics worth $28.3M as of Q2 2026.
  • UBS Group bought 9,512 TG Therapeutics shares in Q2 2026, an estimated $389K.
  • TG Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2320 holding.
  • UBS Group first reported a position in TG Therapeutics in Q4 2014 and has held it in 47 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.